Pituitary Adenoma and Serum Lipid

Effects of Pituitary Adenoma Resection on Serum Lipid Level

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04021212

Enrollment

1000

Registered

2019-07-16

Start date

2020-09-01

Completion date

2024-06-30

Last updated

2022-05-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pituitary Adenoma 1, Acth-Secreting

Keywords

Pituitary, Pituitary Adenoma, Serum Lipid Levels, Resection, Recurrence

Brief summary

Pituitary adenomas are usually benign monoclonal neoplasms caused by a mixture of pituicyte alterations together with a changed endocrine and paracrine regulatory milieu. Thus, it can cause serious health problems such as abnormal target organ function, pain, disability and even death. In clinical practice, we found many patients with pituitary adenomas are usually accompanied by hyperlipidemia, which is the main cause of cardiovascular diseases. However, it has been unclear if there is an association between pituitary adenomas and serum lipid profile. In the present study, we aim to focus on the patients with pituitary adenomas and their lipid profile before and after operation including first occurrence and recurrence.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

1. Patients diagnosed with pituitary adenomas 2. All adenomas were resected by transsphenoidal surgery and identified by histological diagnoses.

Exclusion criteria

1. Missing vital data, such as age, gender, serum lipid profile, pathology reports; 2. Complications or conditions that affect pituitary status and lipid metabolism, such as pregnancy, malignant adenomas or severe hepatic or renal dysfunction and 3. Use of any medication that affects the pituitary or lipid metabolism, including statins, fibrates, thyroid hormones, anti-thyroid drugs, iodine, amiodarone, alemtuzumab, lithium, tyrosine kinase inhibitors, interferon, estrogens, androgens,glucocorticoids, nonsteroidal anti-inflammatory drugs, antiepileptic drugs, rifampicin, furosemide, heparin or β-adrenoceptor blockers in the past 3 months.

Design outcomes

Primary

Measure	Time frame
Change in serum lipid levels	Measured at pre-operative and 6 months after operation

Countries

China

Contacts

Primary ContactLing Gao

linggao@sdu.edu.cn+86 53168776910

Outcome results